266 related articles for article (PubMed ID: 26456120)
1. Targeted proteomics of solid cancers: from quantification of known biomarkers towards reading the digital proteome maps.
Pernikářová V; Bouchal P
Expert Rev Proteomics; 2015; 12(6):651-67. PubMed ID: 26456120
[TBL] [Abstract][Full Text] [Related]
2. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context.
Schaaij-Visser TB; de Wit M; Lam SW; Jiménez CR
Biochim Biophys Acta; 2013 Nov; 1834(11):2242-58. PubMed ID: 23376433
[TBL] [Abstract][Full Text] [Related]
3. Mass spectrometry-based proteomics in cancer research.
Cho WC
Expert Rev Proteomics; 2017 Sep; 14(9):725-727. PubMed ID: 28783987
[No Abstract] [Full Text] [Related]
4. Targeted mass spectrometry approaches for protein biomarker verification.
Meng Z; Veenstra TD
J Proteomics; 2011 Nov; 74(12):2650-9. PubMed ID: 21540133
[TBL] [Abstract][Full Text] [Related]
5. Deciphering the complexity of the cancer proteome for diagnostic applications.
Hanash S; Taguchi A; Wang H; Ostrin EJ
Expert Rev Mol Diagn; 2016; 16(4):399-405. PubMed ID: 26694525
[TBL] [Abstract][Full Text] [Related]
6. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
[TBL] [Abstract][Full Text] [Related]
7. SRM/MRM targeted proteomics as a tool for biomarker validation and absolute quantification in human urine.
Mermelekas G; Vlahou A; Zoidakis J
Expert Rev Mol Diagn; 2015; 15(11):1441-54. PubMed ID: 26472065
[TBL] [Abstract][Full Text] [Related]
8. Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness.
Procházková I; Lenčo J; Bouchal P
Methods Mol Biol; 2018; 1788():177-184. PubMed ID: 29196895
[TBL] [Abstract][Full Text] [Related]
9. Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer.
Ma H; Chen G; Guo M
Proteomics Clin Appl; 2016 Apr; 10(4):503-15. PubMed ID: 26616366
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in clinical proteomics using mass spectrometry.
Dowling P; Meleady P; Henry M; Clynes M
Bioanalysis; 2010 Sep; 2(9):1609-15. PubMed ID: 21083289
[TBL] [Abstract][Full Text] [Related]
11. Characterizing disease-associated changes in post-translational modifications by mass spectrometry.
Thygesen C; Boll I; Finsen B; Modzel M; Larsen MR
Expert Rev Proteomics; 2018 Mar; 15(3):245-258. PubMed ID: 29376447
[TBL] [Abstract][Full Text] [Related]
12. Mass spectrometric protein maps for biomarker discovery and clinical research.
Liu Y; Hüttenhain R; Collins B; Aebersold R
Expert Rev Mol Diagn; 2013 Nov; 13(8):811-25. PubMed ID: 24138574
[TBL] [Abstract][Full Text] [Related]
13. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer.
Shukla HD; Mahmood J; Vujaskovic Z
Cancer Lett; 2015 Dec; 369(1):28-36. PubMed ID: 26276717
[TBL] [Abstract][Full Text] [Related]
14. Targeted Proteomics Guided by Label-free Quantitative Proteome Analysis in Saliva Reveal Transition Signatures from Health to Periodontal Disease.
Bostanci N; Selevsek N; Wolski W; Grossmann J; Bao K; Wahlander A; Trachsel C; Schlapbach R; Öztürk VÖ; Afacan B; Emingil G; Belibasakis GN
Mol Cell Proteomics; 2018 Jul; 17(7):1392-1409. PubMed ID: 29610270
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.
Ryu J; Thomas SN
Molecules; 2021 May; 26(9):. PubMed ID: 34063568
[TBL] [Abstract][Full Text] [Related]
16. Proteomics analysis of bodily fluids in pancreatic cancer.
Pan S; Brentnall TA; Chen R
Proteomics; 2015 Aug; 15(15):2705-15. PubMed ID: 25780901
[TBL] [Abstract][Full Text] [Related]
17. Optomechanical devices for deep plasma cancer proteomics.
Kosaka PM; Calleja M; Tamayo J
Semin Cancer Biol; 2018 Oct; 52(Pt 1):26-38. PubMed ID: 28867489
[TBL] [Abstract][Full Text] [Related]
18. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry.
Elschenbroich S; Ignatchenko V; Clarke B; Kalloger SE; Boutros PC; Gramolini AO; Shaw P; Jurisica I; Kislinger T
J Proteome Res; 2011 May; 10(5):2286-99. PubMed ID: 21491939
[TBL] [Abstract][Full Text] [Related]
19. Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine.
Honda K; Ono M; Shitashige M; Masuda M; Kamita M; Miura N; Yamada T
Jpn J Clin Oncol; 2013 Feb; 43(2):103-9. PubMed ID: 23248327
[TBL] [Abstract][Full Text] [Related]
20. Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach.
Kim YJ; Sertamo K; Pierrard MA; Mesmin C; Kim SY; Schlesser M; Berchem G; Domon B
J Proteome Res; 2015 Mar; 14(3):1412-9. PubMed ID: 25597550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
